Tag:
Afexa Life Sciences
Latest Headlines
Latest Headlines
Hungry for ISTA, Valeant makes bid
Canada's Valeant Pharmaceuticals ( $VRX ) will push for at least one more acquisition before the holidays: U.S.-based rival ISTA Pharmaceuticals ($ISTA). The unsolicited bid for the California-based
Paladin, Valeant raise stakes in bidding for Afexa
Canada's Afexa Life Sciences has sparked a bidding war. This morning, Paladin Laboratories topped Valeant Pharmaceuticals' 71-cents-a-share bid with an 81-cent offer, but Valeant turned around and
Valeant emerges as Afexa's $76M white knight
Sorry, Paladin Labs. Valeant Pharmaceuticals ( $VRX ) has muscled its fellow Canadian drugmaker aside to strike a buyout deal with Afexa Life Sciences. Valeant's white-knight bid is 71 cents per share,
Paladin mounts hostile bid for Afexa
Paladin Labs is offering a modest premium in a hostile bid to take over Afexa Life Sciences, which makes the flu drug COLD-FX. In a deal that values the company at $56.7 million, Paladin has bid 55
